Mortality and morbidity in patients receiving encainide
, flecainide, or placebo.
In the CAST, patients treated with encainide
or flecainide had higher mortality rates after myocardial infarction compared to placebo group .
(21.) Preliminary report: Effect of encainide
and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
anti-arrhythmic drugs Enkaid (encainide
) and Tambocor (flecainide) in
(a) Antiarrhythmic drugs: Class 1A (quinidine, procainamide, and disopyramide), Class 1C (encainide
, flecainide), and Class 3 (sotalol, dofetilide)
Mitchell et al., "Mortality and morbidity in patients receiving encainide
, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial," The New England Journal of Medicine, vol.
 The Cardiac Arrhythmia Suppression Trial (CAST) Investigators, "Preliminary report: effect of encainide
and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction," The New England Journal of Medicine, vol.
Use caution if co-administering BRISDELLE with other drugs that are metabolized by CYP2D6, including nortriptyline, amitriptyline, imipramine, desipramine, fluoxetine, phenothiazines, risperidone, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide
Rogers et al., "Mortality following ventricular arrhythmia suppression by encainide
, flecainide, and moricizine after myocardial infarction: the original design concept of the cardiac arrhythmia suppression trial (CAST)," Journal of the American Medical Association, vol.
Both Cardiac Arrhythmia Suppression Trials (CAST I: encainide
and flecainide; CAST II: moricizine) showed that suppressing frequent PVCs significantly increased mortality in the treatment groups.
or flecainide) or peripheral vasodilators without re-titration has resulted in lethal pro-arrhythmia or hypotension, respectively.
Effects of encainide
, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: The CAPS.